NEVVI Medicare utilization intelligence
or

← back

Provider profile

SHIEH, MARIE MD

Hematology-Oncology · NPI 1245475474 · SAN DIEGO, CA

2
Groups
21
Codes · 2024
55,833
Disclosed services

SHIEH, MARIE is a Hematology-Oncology in SAN DIEGO, CA, a member of 2 medical groups, who billed 21 distinct codes to Medicare Part B in 2024.

Groups: EMERGENCY AND ACUTE CARE MEDICAL CORPORATION (SAN DIEGO, CA) · MEDICAL ONCOLOGY ASSOCIATES OF SAN DIEGO A MEDICAL GROUP INC (SAN DIEGO, CA) — member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

55,833
disclosed services
21
codes billed to Medicare Part B
Prior year · CY2023 8,112 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
36415 Insertion of needle into vein for collection of blood sample
96413 Administration of chemotherapy into vein, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96372 Injection of drug or substance under skin or into muscle
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96375 Injection of additional new drug or substance into vein
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
J3489 Injection, zoledronic acid, 1 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.